The future of preclinical development: AI, advanced models and the next generation of predictive science

The pressure on the pharmaceutical and biotechnology industries to develop new medicines faster, more efficiently and more successfully continues to increase. At the same time, therapeutic challenges are becoming more complex. New modalities, including cell and gene therapies, RNA-based therapies and precision medicine, require a fundamentally different approach to preclinical development.

Traditional research models have provided the foundation for assessing safety and efficacy for decades. Although they continue to play an important role, there is growing recognition that these models are not always sufficiently predictive of human outcomes. Attention is therefore shifting towards innovative technologies that provide a more realistic understanding of how drug candidates will behave in the human body.

For organisations investing in research and development, the question is no longer whether these developments will have an impact, but how they can deploy these innovations strategically to make better decisions and increase the likelihood of clinical success.

From reactive to predictive development

The traditional approach to preclinical development is based largely on generating experimental data and subsequently interpreting the results. With the emergence of artificial intelligence, advanced data analytics and computational models, this approach is increasingly shifting towards predictive decision-making.

Combining large volumes of biological, chemical and clinical data enables organisations to identify patterns that previously remained hidden. This makes it possible to identify potential risks earlier, select drug candidates more accurately and design development programmes more strategically.

The objective is not to replace scientific expertise, but to support decision-making with deeper insights and more reliable predictions.

Artificial intelligence as an accelerator of R&D

AI is rapidly becoming a valuable tool in the preclinical development phase. Machine learning algorithms can analyse large datasets and identify relationships that are difficult or even impossible to detect using traditional analytical methods.

Applications include:

Identifying and prioritising drug candidates;
Predicting toxicological risks;
Optimising molecular properties;
Analysing complex biological datasets;
Supporting biomarker development;
Modelling pharmacokinetic and pharmacodynamic processes.

Although AI holds considerable promise, human expertise remains essential. The quality of algorithms is ultimately determined by the quality of the underlying data, the scientific context and the interpretation of results.

More human-relevant research models

Alongside digital innovation, the way preclinical experiments are conducted is also changing.

Technologies such as organoids, organ-on-a-chip systems and advanced 3D cell cultures can replicate human physiology more accurately than many traditional models. This provides a more realistic understanding of efficacy, safety and potential adverse effects before a drug candidate enters clinical development.

These advances not only improve the predictive value of research, but also support the global movement to reduce animal testing wherever possible and further develop alternative research methods.

Data integration is becoming a strategic capability

Innovation in preclinical development is not solely about new technologies. It is primarily about the ability to connect different data sources.

Genomic data, imaging, biomarker data, toxicology results, pharmacological analyses and clinical knowledge each provide valuable insights independently. The greatest value, however, emerges when this information is integrated into a single coherent decision-making framework.

Organisations that invest in high-quality data infrastructure, digital collaboration and multidisciplinary analysis gain an important competitive advantage. This is not because they collect more data, but because they can make better decisions based on those data.

New technology requires new expertise

The introduction of AI and advanced research models is also changing the role of professionals in preclinical development.

Scientific depth remains as important as ever, but it is increasingly complemented by expertise in data science, bioinformatics, computational biology and digital innovation. At the same time, demand is growing for professionals who can connect these disciplines and translate their collective insights into strategic decisions.

This combination of subject-matter knowledge, technological expertise and experience with complex development programmes is increasingly determining the success of innovative R&D organisations.

Innovation requires critical judgement

Although new technologies offer significant possibilities, a realistic approach remains essential. Not every innovation automatically produces better results. New models must be scientifically validated, integrated into established development processes and aligned with regulatory expectations.

Successful organisations are therefore distinguished not by being the first to implement the latest technology, but by carefully assessing where innovation genuinely contributes to better decision-making, higher quality and a greater likelihood of clinical success.

The next generation of drug development

The future of preclinical development will be characterised by closer collaboration between science, technology and data. Artificial intelligence, human-relevant research models and integrated predictive analytics will play an increasingly important role in selecting and developing new therapies.

One principle, however, remains unchanged: technology is only as valuable as the decisions it enables. Ultimately, experienced professionals bring together scientific insights, technological innovation and strategic considerations to create a robust development programme.

Organisations that combine these disciplines effectively not only create more efficient development pathways, but also increase the likelihood that promising innovations will ultimately become safe and effective treatments for patients. The next generation of preclinical development therefore represents not only a technological evolution, but also a fundamental transformation in how medicines are developed.

Working with Maxwell Benson? Discover the possibilities

Werken met Oliver Benson?